Media

Race Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via this link.

Race Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its Phase 1 clinical trial for RC220, a new formulation of bisantrene. The full report can be accessed via this link.

Race CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link.

Race CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness.

Proactive reports on the outlook of the oncology therapeutics market, naming Race Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link.

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC). Watch the video via this link

Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also reported promising results from a phase 1b/2 trial using the original bisantrene formulation (RC-110) in treating acute myeloid leukemia.  Read the…

As seen in The Australian, Dr Megan Baldwin joins the Race board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and Chief Innovation Officer at Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need…

Proactive reports on Race’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here.